Debt-to-equity of Xeris Biopharma Holdings, Inc. from 30 Jun 2022 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Xeris Biopharma Holdings, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2022 to 31 Dec 2025.
  • Xeris Biopharma Holdings, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was -3474%, a 115% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Xeris Biopharma Holdings, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 -3474% -1855% -115% 31 Dec 2025
Q3 2025 -1682% +482% +22% 30 Sep 2025
Q2 2025 -1252% +3051% +71% 30 Jun 2025
Q1 2025 -1249% -86258% -101% 31 Mar 2025
Q4 2024 -1619% -4709% -152% 31 Dec 2024
Q3 2024 -2164% -3490% -263% 30 Sep 2024
Q2 2024 -4302% -5104% -637% 30 Jun 2024
Q1 2024 85009% +84478% +15925% 31 Mar 2024
Q4 2023 3090% +2708% +709% 31 Dec 2023
Q3 2023 1326% +1032% +351% 30 Sep 2023
Q2 2023 802% +487% +155% 30 Jun 2023
Q1 2023 530% 31 Mar 2023
Q4 2022 382% 31 Dec 2022
Q3 2022 294% 30 Sep 2022
Q2 2022 315% 30 Jun 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.